Sign in
Taking peopleNo phase

Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment

Key facts

Who runs it
Qilu Hospital of Shandong University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
74 people, planned
Started
10 Sept 2024
Expected to end
30 Dec 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • anti-reflux mucosal valvuloplasty (ARMV)
Record updated
18 November 2024

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • 18-60 years of age
  • Hiatal hernia ≤ 2 cm
  • Sliding hernia ≤ 2 cm
  • Recurrence of GERD symptoms after cessation of PPIs
  • On daily PPI for ≥1 year or twice daily PPI for at least 8 weeks
  • Esophagitis (Los Angeles Classification) Grade B, C, or D
  • Hill's flap valve grade ≤ III
  • Observation of distal esophageal pH < 4 on at least 1-2 days within a 7-day period, with a percentage exceeding 5.3%
  • Normal or near-normal esophageal motility
  • Lower esophageal sphincter pressure (LESP) ranging between 5-15 mmHg
  • DeMeester score ≥ 14.7 or total reflux episodes exceeding 73
  • Completion of a signed informed consent form

Who cannot take part

  • History of previous esophageal or gastric surgery, including ARMS or ARMA
  • Peptic ulcer disease
  • Primary esophageal motility disorders such as achalasia
  • Uncontrolled systemic diseases
  • BMI > 35 kg/m2
  • ASA > II
  • Barrett's esophagus
  • Hiatal hernia > 2 cm
  • Esophagitis (Los Angeles Classification) Grade A or No esophagitis;
  • Hill's flap valve grade > III;
  • Severe gastroparesis
  • Gastric outlet obstruction
  • Pregnancy or planning to become pregnant

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study objective is to evaluate the relative merits, safety and effectiveness of Anti-reflux mucosal valvuloplasty (ARMV) in GERD patients currently treated with daily Proton Pump Inhibitors (PPIs).

The 2 groups in the trial

  • ARMV (intervention group)Treatment being tested

    Under general anesthesia, patients are positioned in the left lateral decubitus position and undergo endoscopic examination of the esophagus and stomach. The surgery utilizes a single-channel gastroscope (EG29-i10, Pentax, Japan, or GIF-H290T, Olympus, Japan) and a high-frequency generator (VIO300D, Erbe, Germany). A transparent cap (D-201, Olympus, Japan) is attached to the gastroscope to improve visualization and aid in manipulating the flap valve. The DualKnife (Olympus, Japan) is selected for dissection due to its maneuverability in a retroflexed fashion. For patients with esophageal strictures obstructing scope passage, esophageal dilation is performed using Savary-Gilliard dilators (Cook Medical, USA) just before ARMV.

    Treatment: anti-reflux mucosal valvuloplasty (ARMV)

  • PPI (control group)No study treatment, for comparison

    Patients randomized to the PPI group will follow the PPI treatment scheme. If GERD symptoms are effectively controlled with their current PPI dosage for at least one month, the regimen is decreased by one step. Conversely, if symptoms are poorly controlled, the dosage is increased by one step based on the PPI algorithm, which aligns with best clinical practices. The use of PPI will be recorded in medication diaries using generic names listed in the table below and classified according to the daily dose and frequency. Dosage will be categorized as "double dose" = ≥30 or 40 mg per day, "full dose" = 30 or 40 mg per day, "half dose" = 15 or 20 mg per day, "occasional" or "on demand" = \< "full dose" taken for \< 50% of days in the follow-up period. Common medications include Nexium 20mg、Prevacid 30mg、Prilosec 20mg、Protonix 20mg、Aciphex20mg.The frequency of medication use is once a day.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anti-reflux Mucosal Valvuloplasty Versus Proton Pump Inhibitors for the Treatment of Patients With Gastroesophageal Reflux Disease in a Tertiary Healthcare Center in China: Study Protocol for a Randomized Controlled Trial
Criteria questions
Built from NCT06348420, who can take part
Publications
Record updated
18 November 2024